Info
Description
Lung biopsy is the definitive method of lung cancer diagnosis but unfortunately 1 in 3 patients suffer from a collapsed lung: a pneumothorax. Selio will eliminate this common, costly and dangerous complication thereby preventing significant patient morbidity & expensive hospital admissions post lung biopsy for invasive treatment. Selio adopts a revolutionary approach by preventing the pneumothorax occurring before the biopsy even takes place. Selio is a single use, smart device that temporarily seals the needle access route into the lung before the biopsy even takes place. The biopsy is then performed through the Selio air tight seal preventing any air leak from the lung during or after the procedure and so eliminating the risk of pneumothorax. Customers are interventional radiologists carrying out lung biopsy procedures, mostly in outpatient centres under CT guidance. A pneumothorax causes the patient significant pain, distress and difficulty breathing. In severe cases, it is life threatening. A pneumothorax converts a routine outpatient diagnostic procedure to one requiring hospitalisation and invasive treatment at an average cost of $11,000 per patient.
Selio is a simple, effective and patent protected technology. The Selio prototype has been rigorously tested in the lab and in subsequent acute pre-clinical in vivo studies with very positive results.
Expected milestones:
- Q4 2017: Chronic recovery pre-clinical study.
- Q1 2018: Spin out technology from Trinity College Dublin.
- Q1 2018: FDA pre-submission meeting.
- Q3 2018: First in Man Study.
We have raised €530k in non-dilutive grant funding and are now raising a Series A of €3.5m which will bring the technology through FDA and CE mark submissions by 2021.
